The great thing about getting older is that you always have something to talk about with other old people at a dinner table—your medical problems.  And sterile inflammaging:  chronic, low-grade inflammation without an infectious trigger. It’s one of the constant companions of old age and now considered one of the central drivers of aging. What makes it different from “regular” chronic inflammation is its source. There’s no virus, no bacterial infection, no autoimmune misfire to point at. The inflammation is generated from within—by the body’s own aging cells, tissues, and metabolic byproducts.

Most adults over 65 show measurable elevations in inflammatory markers compared to younger people, and these elevations track closely with frailty, disability, and overall mortality. The phenomenon is so consistent across populations that researchers describe it as a near-universal feature of human aging, distinct from acute or pathogen-driven inflammation.  Besides CRP and ESR, the traditional quick and dirty measures of inflammation, there are some new composite measures that combine multiple inflammatory and biological aging signals:

• Interleukin-6 (IL-6)
• TNF-alpha
• Multi-cytokine panels that capture a broader inflammatory signature than any single marker
• DNA methylation clocks (epigenetic age) that correlate with inflammatory burden
• Glycomics, metabolomics, and lipidomics profiles that detect age-related shifts in circulating molecules
• Immune cell profiling—particularly the ratio of naive to memory T cells, and the accumulation of senescent immune cells like clonal GZMK+ CD8+ T cells, which has emerged as a conserved hallmark of inflammaging

What causes it?

Inflammaging results from several aging processes that all happen to feed inflammation.

• Cellular senescence. As cells accumulate damage, some stop dividing but refuse to die. These “zombie” cells secrete a cocktail of inflammatory molecules called the senescence-associated secretory phenotype, or SASP—cytokines, chemokines, proteases, and reactive oxygen species. A small population of senescent cells can inflame an entire tissue, and their numbers grow steadily with age.
• Mitochondrial dysfunction. Aging mitochondria leak more reactive oxygen species and release damaged mitochondrial DNA into the cell. The immune system reads this leaked DNA as a danger signal—essentially mistaking it for bacterial DNA—and mounts an inflammatory response.
• The immune system itself ages. The thymus shrinks, T cell diversity drops, and T cell lineages shift to inflammatory subtypes.  Innate immunity becomes less precise—quicker to inflame, slower to resolve. Aged immune cells are themselves a major source of inflammatory cytokines.
• Gut microbiota changes. With age, the gut barrier becomes more permeable and the microbiome shifts toward more pro-inflammatory species. Bacterial fragments leak into circulation and trigger systemic immune activation.
• Visceral fat—is metabolically active tissue that produces inflammatory signals. The overlap between metabolic disease and inflammaging is so strong that researchers often discuss them together.
• Defective autophagy. Cells lose the ability to efficiently clear damaged proteins and organelles. The cellular debris itself becomes inflammatory.

These mechanisms reinforce each other. Senescent cells damage mitochondria. Damaged mitochondria activate immune cells. Aging immune cells fail to clear senescent cells.

What are the consequences?

Inflammaging is now linked to most major age-related diseases—not as a side effect, but as a contributor.

• Cardiovascular disease. Chronic vascular inflammation drives atherosclerosis, endothelial dysfunction, and stiffening of arteries.
• Neurodegeneration. Inflammatory signaling contributes to Alzheimer’s, Parkinson’s, and age-related cognitive decline. The aging brain shows microglial activation and cytokine elevation that parallels systemic inflammaging.
• Sarcopenia and frailty. Inflammatory cytokines accelerate muscle protein breakdown and impair regeneration.
• Type 2 diabetes and metabolic syndrome. Inflammation interferes with insulin signaling and pancreatic function.
• Cancer. Chronic inflammation creates a tissue environment that favors tumor development and progression.
• Cerebral small vessel disease. Inflammation damages the blood-brain barrier and the small vessels that supply deep brain structures.
• Kidney disease. Inflammaging accelerates fibrosis and impairs kidney regeneration.

Looked at this way, many seemingly separate diseases of aging share a common inflammatory undercurrent. This is part of why interventions targeting inflammaging have such broad potential—they don’t treat one disease, they target an upstream driver of many.

How do we prevent and treat it?

Inflammaging is modifiable. While we can’t stop aging, we can reduce the inflammatory burden, and the evidence here keeps growing.

Lifestyle foundations

The interventions with the strongest and most consistent evidence are also the most accessible.

• Physical activity. Regular exercise lowers IL-6 and CRP, improves immune function, reduces visceral fat, and clears senescent cells from some tissues. Both aerobic and resistance training contribute, and the benefits show up even when exercise begins later in life.
• Anti-inflammatory diet. Diets emphasizing polyphenol-rich plants, omega-3 fatty acids (from fatty fish, walnuts, flax), olive oil, and minimally processed foods consistently lower inflammatory markers. Mediterranean and traditional Japanese eating patterns are the best-studied examples.
• Caloric restriction and intermittent fasting. Both reduce inflammatory signaling, improve metabolic health, and trigger autophagy—the cellular cleanup that clears damaged components before they become inflammatory.
• Sleep.  Inadequate or fragmented sleep elevates inflammatory cytokines within days. Consistent, sufficient sleep is one of the most underrated anti-inflammatory interventions.
• Stress management. Chronic psychological stress activates inflammatory pathways through HPA axis dysregulation. Meditation, social connection, and stress-reduction practices have measurable effects on inflammatory markers.

Emerging pharmaceutical therapies

Not nearly as effective as lifestyle measures, but worth mentioning.

• Senolytics are drugs and natural compounds that selectively eliminate senescent cells. The combination of dasatinib and quercetin has shown promise in early human trials. Fisetin, a flavonoid found in strawberries, is also being studied. The idea is simple: clear the zombie cells, and you remove a major source of SASP-driven inflammation.
• Senomorphics don’t kill senescent cells but suppress their inflammatory output—useful when wholesale removal isn’t feasible.
• Targeted immunomodulators. IL-11 inhibitors, TLR-modulating compounds, and inflammasome-targeted therapies are in development. Not ready for prime time.
• Probiotics and prebiotics. Restoring gut microbial balance can reduce systemic inflammatory load, particularly when combined with dietary fiber.
• Metformin and rapamycin have both shown anti-inflammaging effects in research settings, though their use specifically for healthspan extension remains investigational.
• NAD+ precursors (such as nicotinamide riboside and NMN) support sirtuin function, which helps regulate inflammatory signaling and mitochondrial health.

Medical treatment of inflammaging has its strongest clinical validation in two landmark trials:

• CANTOS (2017) — The first major proof of concept. Over 10,000 patients with prior heart attack and elevated CRP received canakinumab (an IL-1β–blocking antibody) or placebo. The drug lowered hsCRP by 26-41% with no effect on cholesterol. The 150 mg dose reduced the primary endpoint (non-fatal MI, stroke, or cardiovascular death) by 15% over 3.7 years. This was a watershed result — it proved that reducing inflammation alone, independent of lipid-lowering, prevents cardiovascular events. Sadly, all-cause mortality didn’t improve because reduced cancer mortality was offset by an increase in fatal infections — a reminder that suppressing immunity has real costs in older people.
• COLCOT and LoDoCo2 — These trials tested low-dose colchicine (a cheap, generic anti-inflammatory) in heart disease patients. Both showed reductions in atherosclerotic cardiovascular events, but not mortality. In 2023, the FDA approved colchicine 0.5 mg once daily for the secondary prevention of cardiovascular disease — making it the first approved drug specifically for the inflammatory component of heart disease.
• The STAMINA pilot (published 2025) tested dasatinib + quercetin in 12 older adults with mild cognitive impairment and slow gait. It was small, single-arm, and uncontrolled, but: MoCA cognitive scores improved by 1 point on average and by 2 points significantly in those with the lowest baseline scores; stride length tended to improve; no serious adverse events occurred. This is a tiny study and probably not even worth mentioning until larger randomized trials result.

There are no completed trials yet showing that lowering inflammation extends lifespan or broadly improves healthspan in healthy older adults. The evidence we have is almost entirely from people who already have cardiovascular disease. Whether reducing inflammaging in generally healthy aging adults prevents future disease remains an open question being actively tested.

Inflammaging reframes how we think about aging. It suggests that many of the diseases we accept as inevitable consequences of getting older share a common, addressable upstream driver. The same processes that age your immune system are aging your blood vessels, your brain, your muscles, and your metabolism—all at once.

That’s bad news in the sense that the problem is systemic. But it’s also good news: a single intervention that meaningfully lowers inflammation can ripple across multiple organ systems. Exercise, diet, sleep, stress reduction, and emerging targeted therapies hit a shared mechanism.